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Abstract Resource-limited regions of the world represent
the areas most affected by the global HIV epidemic.
Currently, there are insufficient data on the neurocognitive
effects of HIV in these areas and neuropsychological
studies that have been carried out thus far are marked by
inconsistent methods, test batteries, and rating systems for
levels of cognitive impairment. These differences in
methods, along with genetic variability of both virus and
host, differences in co-infections and other co-morbidities,
differences in language and culture, and infrastructural
deficiencies in many international settings create challenges
to the assessment of neurocognitive functioning and
interpretation of neuropsychological data. Identifying neu-
rocognitive impairment directly attributable to HIV, explor-
ing relationships between HIV-associated neurocognitive
impairment, disease variables, and everyday functioning,
evaluating differences in HIV-1 subtype associated neuro-
pathology, and determining implications for treatment
remain complicated and challenging goals. Endeavors to
establish a more standardized approach to neurocognitive
assessments across international studies in addition to
accumulating appropriate normative data that will allow
more accurate rating of neuropsychological test perfor-
mance will be crucial to future efforts attempting to achieve
these goals.
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Introduction
The establishment of highly active antiretroviral therapy as
the mainstay of HIV treatment in developed nations has led
to impressive reductions in the prevalence of severe HIV-
associated neurocognitive disorders (HAND) and central
nervous system (CNS) opportunistic infections. Accounts
of HIV-associated dementia in these settings are now
generally limited to patients who are either treatment naïve
or are failing therapy due to viral drug resistance or
problems with adherence. Milder forms of neurocognitive
dysfunction, however, are still prevalent and continue to be
under recognized in patients on antiretroviral therapy. Most
of the studies to date investigating the action of highly
active antiretroviral therapy at improving neurological and
cognitive dysfunction have been carried out in the resource
intense settings of the US, Europe, and Australia. Resource-
limited communities in Sub-Saharan Africa, Asia, and the
rest of the developing world, however, represent the areas
most devastated by the HIV epidemic. These areas offer
considerable potential for research and stand to gain the
most from effective therapy.
Neuropsychological assessments are arguably the most
important tools for diagnosing and categorizing HIV effects
on the CNS. Especially in resource-limited settings, where
sophisticated neuroimaging technology often is unavailable,
characterization of neurocognitive functioning through
neuropsychological assessments is crucial to successful
diagnosis and treatment. When assessments are reliable and
valid, and appropriate normative standards exist, they are
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quite sensitive to even milder forms of CNS compromise
and also may provide valuable estimates of functional
impairment. This article presents a review of the current
status, as well as the potential, and some challenges to
conducting neuropsychological assessments in resource-
limited settings, with a focus on HIV-infected populations.
Global Epidemiology of HIV and HAND
HIV is a truly global disease, affecting roughly 33
million people all over the world. The number of people
infected with HIV in the United States, Western Europe
and Oceania however represent only 4% of worldwide
infections (Hemelaar et al. 2006). Most of the people
infected or affected by HIV live in developing countries
where cultural values, social influences, educational
opportunities and access to other resources are clearly
distinct from those in the West. Africa and the Middle East
account for over 66% of worldwide infections, Asia for
over 20%, Eastern Europe and Central Asia for approxi-
mately 4%, and Latin America and the Caribbean for
around 6% (Hemelaar et al. 2006).
In addition to the wide dispersion of HIVaround the world,
the rapid evolution of the virus itself has led to considerable
genetic variation in a relatively short period of time. In West
Central Africa, where the original cross-species transmissions
are believed to have occurred (Gao et al. 1999), almost all of
the nine major subtypes of HIV-1 Group M (A-D, F-H, J,
and K), as well as strains of HIV-1 Groups N and O, and
HIV-2 can be found. In other parts of Africa and other
regions of the world however (Fig. 1), certain subtypes and
recombinant forms such as CRF01_AE and CRF02_AG
predominate over others (Hemelaar et al. 2006). The
extensive genetic diversity that characterizes HIV along with
the geographic compartmentalization of viral species raises
interesting and challenging questions in regards to associated
differences in disease progression (systemic and neurologi-
cal), effectiveness of antiretroviral therapy, and the outlook
of the constantly evolving pandemic.
Neuropsychology of HIV Infection
Neuropathology
HIV-1 enters the CNS early during the course of infection
(An et al. 1999; Davis et al. 1992) and frequently results in
neurological disease marked by a set of cognitive, motor,
and behavioral symptoms (Chiodi et al. 1992; Navia et al.
Fig. 1 Regional distribution of major HIV-1 Subtypes. *Map of regional distribution of major HIV-1 subtypes borrowed from cover of August
2007 issue of Journal of NeuroVirology, used with permission from the publisher. (Liner et al. 2007)
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1986b). The significant loss of neurons and neuronal
processes (e.g. dendritic complexity) in people dying of
AIDS clearly correlates with ante-mortem neurocognitive
impairment (Masliah et al. 1992, 1997; Mattson et al.
2005). Cells primarily infected by HIV within the CNS are
blood-derived macrophages, resident microglia, and per-
haps astrocytes, but most studies suggest that neurons are
not directly infected (Epstein and Gendelman 1993; Kure et
al. 1990; Takahashi et al. 1996; Trillo-Pazos et al. 2003).
The neuronal damage that occurs is likely caused by shed
viral proteins such as gp120 (Dreyer et al. 1990; Lannuzel
et al. 1995) and Tat (Behnisch et al. 2004; Jones et al. 1998;
Maragos et al. 2003; Nath et al. 1999) or indirectly through
the elevated production of neurotoxic molecules released by
activated astrocytes (Levi et al. 1993; Merrill et al. 1992;
Mollace et al. 1993; Nath et al. 1999; Patton et al. 2000),
macrophages (Gendelman et al. 1994; Levi et al. 1993;
Merrill et al. 1992; Nath et al. 1999), and microglia
(Gendelman et al. 1994; Jones et al. 1998; Kramer-
Hammerle et al. 2005; Levi et al. 1993; Mattson et al.
2005; Nath et al. 1999). HIV infection in the brain has
widespread and variable effects but appears to preferentially
cause damage to the basal ganglia and deep white matter
(Navia et al. 1986a). However, damage to cortical and
subcortical neurons (hippocampus and putamen) (Archibald
et al. 2004; Everall et al. 1999; Moore et al. 2006),
particularly dendritic pathology (Masliah et al. 1997) also
are likely to play a role in CNS disease manifestations.
Nomenclature
The nomenclature of HIV related neurological diagnoses
was recently revised and updated (Antinori et al. 2007), but
there are a number of terms used in the existing literature
worth discussing for purposes of clarity. Navia et al.
initially recommended the term AIDS Dementia Complex
to label the severe neurocognitive loss and neurological
dysfunction associated with advanced immunodeficiency
(Navia et al. 1986b). Later the American Academy of
Neurology suggested HIV Associated Dementia as a better
label (AAN 1991). AIDS Dementia Complex and HIV
Associated Dementia have since been used interchangeably.
Patients with some degree of cognitive impairment but
whom did not meet criteria for dementia were classified as
having Minor Cognitive Motor Disorder in the AAN
nomenclature although, especially in the neurological
literature, milder forms of neurocognitive disturbance
sometimes have been classified as a lower stage of
“dementia” (e.g. Memorial Sloan-Kettering (MSK) scale
for dementia: 1-mild, 2-moderate, 3-severe, 4-end stage,
mute) (Price and Sidtis 1990).
With true HIV Associated Dementia, patient profiles
were marked by severe behavioral changes, attention and
executive dysfunction, psychomotor slowing, and memory
impairment (Bornstein et al. 1993; Stern et al. 2001). Minor
Cognitive Motor Disorder patient profiles were characterized
by impaired cognitive and motor speed, working memory,
and new learning, but most aspects of language (except
fluency) and long term memory (semantic) were relatively
unimpaired. As the scope of cognitive dysfunction in HIV
infection has become more evident, it has been suggested that
for research and epidemiological purposes HIV-Associated
Neurocognitive Disorders (HAND) be used as a more
comprehensive title, with three broad subdivisions depending
on the degree of cognitive impairment and associated changes
in everyday functioning: Asymptomatic Neurocognitive
Impairment, HIV-associated Mild Neurocognitive Disorder,
and HIV-Associated Dementia. Asymptomatic Neurocogni-
tive Impairment is defined by performance at least 1 standard
deviation (SD) below the mean of demographically adjusted
normative scores in at least two cognitive areas (attention-
working memory, speed of information processing, language,
abstraction-executive, complex perceptual motor skills,
memory, including learning and recall, simple motor skills
or sensory perceptual abilities), but without any apparent
changes in activities of daily living. Mild Neurocognitive
Disorder, previously referred to as Minor Cognitive and
Motor Disorder, features the same test performance criteria as
above, but with notable changes (at least mild) in activities of
daily living. HIV-Associated Dementia requires performance
of at least 2 SD below demographically corrected normative
means in at least two different cognitive areas, as well as
marked difficulty in activities of daily living due to cognitive
impairment (Antinori et al. 2007). Diagnosis of all three
forms of HAND also requires a determination that the ob-
served neurocognitive impairment and/or functional distur-
bance cannot be explained by co-morbid (non-HIV related)
conditions.
Now that the severe forms of HAND are far less
common, this classification system has been geared more
towards mild and even asymptomatic impairment. As a
consequence, the new system may give better estimates of
neurocognitive disorders than AIDS Dementia Complex
and Memorial Sloan-Kettering ratings which have caused
some confusion by using the term “dementia” to describe
impairment on a number of levels. The AIDS Dementia
Complex and Memorial Sloan-Kettering ratings were
initially proposed at a time when it was not clear that the
milder and more severe forms may be separate entities and
that the milder forms do not necessarily progress to HIV-
associated dementia. This updated classification system,
based on both neuropsychological test performance and
effects on activities of daily living, also represents a
positive step towards more consistent comparison of
individuals and groups across studies and cultures. We
must keep in mind however that the use of specific
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neuropsychological tests and screening instruments still
varies significantly from study to study (Butters et al. 1990;
Clifford et al. 2007; Cysique et al. 2007b; Heaton et al.
1995; Maj et al. 1994; Robertson et al. 2007a, 2008; N. C.
Sacktor et al. 2005; Wilkie et al. 2004; Woods et al. 2006;
Yepthomi et al. 2006)
Patterns of Neurocognitive Dysfunction
HIV infection characteristically generates a “sub-cortical”
pattern of neurocognitive dysfunction with deficits predom-
inantly affecting executive functions, speed of information
processing, attention/working memory, motor speed, new
learning and retrieval of new information, while long term
(semantic) memory, many language skills, and visuo-spatial
abilities may remain intact (Dawes et al. 2008; Grant et al.
1987; Heaton et al. 1995). This average pattern of
neuropsychological impairment, reported by numerous
studies before and after the advent of highly active
antiretroviral therapy, has shaped the development of
current and future test batteries used across the US and
internationally.
The pattern of neurocognitive dysfunction, however, is
not consistent across individuals (Dawes et al. 2008) and
may be even less consistent across individuals from
markedly different backgrounds. Individuals exhibit con-
siderable variation in strength and weakness of ability
domains such as verbal memory, visual memory, processing
speed, attention/working memory, executive function, and
motor skills. Some may exhibit strong motor skills with
weak executive functions and verbal memory, some may
retain processing speed but show decreased visual memory
and executive functions, and still others may feature strong
memory but weak motor skills (Dawes et al. 2008). Test
batteries used in international settings tend to be limited to
fewer of the ability domains above, and to have a fixed
focus on effects of fronto-striatal and white matter
involvement. As such, a battery focused on motor skills
and verbal learning may miss significant impairment in
processing speed and attention, or vice versa. Differences in
patterns of dysfunction may be due to differences in HIV
neuropathology and co-morbid conditions. Distinct patterns
of co-morbidities, such as higher rates of intravenous drug
use in the US compared to high prevalence of Hepatitis C
in rural China (Heaton et al. 2008) may have varying
effects on the CNS and performance on neuropsychological
testing. In some cases the impact of CNS opportunistic
infections or prior injury or illness may entirely preclude
the detection of any direct effects of HIV on the nervous
system. Determining the biological and environmental
sources of these different patterns of impairment, and how
they affect activities of daily living, remain important goals
of HIV research in both the US and internationally. In
addition, any evolving changes in neurological outcomes
may be missed by prior and even ongoing studies that use
focused test batteries tailored to fronto-striatal and white
matter involvement. For example, if older people are more
represented in a study population, more “cortical” patterns
may occur, but may be missed by assessment focused on
sub-cortical dysfunction. Extensive batteries frequently
used for neuropsychological assessments in the US may
cover a wide range of abilities, but may not be an option for
studies in resource-limited settings due to limitations in
time, local expertise, and availability of valid test instru-
ments and norms. It should be kept in mind however that,
especially in this evolving epidemic, we cannot assume that
neurocognitive abilities not assessed by the test battery
being used are unaffected. Unfortunately, even if we change
(expand) our batteries now, at the expense of considerable
time, money and resistance from other colleagues in the
field, there will be little previous data to compare with the
new findings.
Aims of Neuropsychological Assessments
Some of the major goals of neuropsychological evaluations
in HIV-infected populations include:
1. Finding neurocognitive impairment directly attributable
to HIV
2. Determining if neurocognitive impairment is associated
with co-morbid factors such as psychiatric illness,
nutritional deficiencies, or co-infections
3. Exploring relationships between neurocognitive impair-
ment and HIV disease variables such as history of
immunodeficiency (current and nadir CD4 count), viral
load, biomarkers of HIV neuropathogenesis, neuro-
imaging, and brain pathology
4. Exploring the relationship between HIV-associated
neurocognitive impairment and everyday functioning
within different populations around the world
5. Determining implications for treatment including
adherence and use of CNS penetrating antiretroviral
regimens
6. Determining when to start treatment to protect the CNS
from damage and promote continued quality of life/
productivity over the lifespan.
7. and Providing feedback to patients and clinicians on
progress of disease and treatment effects.
Determining the relative impact of HIV and co-morbid
factors on neurocognitive impairment is an important but
very complicated enterprise. In most areas of the world it is
rare to have HIV infected people without co-morbidities. A
recent effort to examine the prevalence and nature of
HAND in association with disease and treatment in a large
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unselected US sample found that fewer than 10% of
patients were considered to have no co-morbidities and in
fact most had 2 to 3 problems (Heaton et al. 2009).
Clinicians and investigators must consider the advantages
and disadvantages of screening and excluding co-
morbidities (some or all) in studies of HIV-infected
populations. Excluding co-morbidities, especially in
resource-limited settings like sub-Saharan Africa, renders
the sample less representative of the broader HIV-infected
population, but engenders more confidence that any
impairment discovered is directly due to HIV. In addition,
the prevalence and impact of various co-morbidities may
vary across international settings. TB, malaria, syphilis,
Hepatitis C, and malnutrition for example, are much bigger
problems in the developing world than in the US and other
developed countries, and the impact of each can vary across
regions. Where the neurological effects of opportunistic
infections preclude determining the direct effects of HIV,
researchers and clinicians should attempt to clearly distin-
guish patients with significant CNS opportunistic disease
from those with HIV-associated neurocognitive disorders.
Another major problem is that clinicians have not been
consistent or reliable in how they rate co-morbid factors
(singly and in combination). The Frascati report (Antinori
et al. 2007) attempted to provide better guidelines for
classifying co-morbidities by specifying and giving rules
for three levels of co-morbidity. In order to better guide
“clinical judgment” about this important issue, however,
there needs to be more research in both Western and non-
Western regions regarding the neuropsychological impacts
of different co-morbidities within the context of HIV
infection. For example, determining how certain co-
morbidities affect rates of neurocognitive impairment and
the likelihood of being able to show relationships between
neurocognitive impairment and HIV disease variables (e.g.
nadir CD4, viral loads, treatment effects, biomarkers
reflecting inflammation, etc.) are two areas of interest.
Infectious Disease specialists may not be expert in all the
conditions of importance in making co-morbidity classi-
fications (e.g. psychiatric disorders, depression, and devel-
opmental conditions such as learning problems), but
involving experts relating to every possible area of concern
is not a practical option for most international HIV studies.
People have assumed that depression can have a much
more robust effect on neuropsychological impairment than
the available data would support, and past histories of
substance use disorders may not be as important as many
clinicians assume (Heaton et al. 1995). Cysique et al.
(2007a) reported that even incident major depression did
not affect neuropsychological function in an ambulatory
group of HIV-infected men (Cysique et al. 2007a).
Goggin et al. (1997) did not find significant differences in
global neuropsychological impairment between groups of
depressed and non-depressed HIV-infected individuals and
did not observe a relationship between severity of depres-
sion and neurocognitive impairment (Goggin et al. 1997).
Authors reported that these findings may be the result of
HIV disease overriding the effects of depression, but this
does not explain normal cognition in many HIV-infected
persons who are also depressed (Cysique et al. 2007a;
Goggin et al. 1997). Possibly the biggest problem facing
assessment of the impact of individual co-morbid condi-
tions is the reality that in the world of clinical practice, one
rarely sees people with just a single co-morbid issue, and
gathering meaningful data on the significance of each issue
may be difficult.
Exploring the relationships between neurocognitive
impairment and everyday functioning presents another
complex area of investigation. Clinicians must rely primar-
ily on patient self-reports which may be influenced by
depression, degree of insight, and complexity of everyday
activities. The same neuropsychological deficits may have
very different everyday consequences for different people
and even different international populations with more, less
or just different requirements for specific cognitive abilities
in their everyday lives. For example, the exact same
neuropsychological pattern which yields a Mild Neuro-
cognitive Disorder or HIV-Associated Dementia classifica-
tion in most areas of the US may not affect everyday
functioning in Uganda or rural China. Even the same
person with the exact same neurocognitive impairment may
have no problems functioning in the rural area but may be
seriously handicapped if he travels to the city for work.
While depression symptoms can account for significant
variance in self-reported neurocognitive complaints
(Rourke et al. 1999), one should not entirely dismiss
subjective cognitive complaints related to everyday func-
tion (Sadek et al. 2007). Biases or subjectivity involved in
self-reports may be part of the issue in determining the
impact of depression and other co-morbidities on everyday
life in each setting, but the actual degree or severity of
depression or other co-morbid condition may be more
important. When classification systems factor in surveys of
activities of daily living, seemingly different disease entities
may end up with the same label and make comparing
classifications across different populations very difficult. A
positive step in this area was the Frascati conference
consensus to acknowledge as a potentially significant
condition, so-called “Asymptomatic Neurocognitive Im-
pairment,” to classify individuals with HAND if they have
deficits on neuropsychological testing but no reported
difficulties with activities of daily living (Antinori et al.
2007; Cherner et al. 2007). As this classification gains more
widespread use, research is needed to clarify the relative
long term importance (especially biological significance, if
any) of the distinction between “asymptomatic” versus
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symptomatic conditions. For now, maintaining a primary
focus on impairment itself, based on objective neuropsy-
chological test performance, may be more reliable and valid
than including activities of daily living, especially for
comparison across different international settings.
HIV-Associated Neurocognitive Disorders in Developed
and Developing Settings
Prior to the era of highly active antiretroviral therapy, the
cumulative risk of developing HIV associated dementia was
estimated to be between 15–20% (McArthur et al. 1993).
Incidence of HIV dementia in the MACS cohort was
estimated to decrease by 53% from 21.1 per 1,000 person-
years between 1990 to 1992, to 10.5 per 1,000 person-years
between 1996 to 1998 (Sacktor et al. 2001). Although
definitions used vary from the current HAND rubric, these
estimates illustrate the decrease in the incidence of
dementia with the introduction of highly active antiretro-
viral therapy, and the seemingly paradoxical finding of
increased prevalence of dementia with patients surviving
longer. The clinical spectrum of the disease has shifted from
the severe and devastating form of dementia commonly
encountered in association with advanced AIDS (typically
end-stage disease) before the introduction of protease
inhibitors and highly active antiretroviral therapy, to the
milder and more manageable forms of HAND. More recent
studies conducted in patients on highly active antiretroviral
therapy, estimate that the prevalence of neurocognitive
dysfunction (based on neuropsychological assessments) in
HIV populations ranges from 20–37%, even with treatment
(Robertson et al. 2007b; Sacktor et al. 2001; Sacktor et al.
2002). The CHARTER study group recently presented
findings from comprehensive neuropsychological evalua-
tions (lasting 2 to 2.5 h) on a large unselected population of
1,555 HIV-positive patients and reported that, overall, 45%
of the cohort had neurocognitive impairment based on a
global neuropsychological rating, although prevalence of
impairment also varied considerably based upon levels of
co-morbidity (Heaton et al. 2009).
Clinical accounts of sub-acute or progressive cognitive
and motor decline are now uncommon and may be limited
primarily to treatment naïve patients, patients with adher-
ence issues, or those experiencing treatment failures (Liner
et al. 2008; Price and Spudich 2008). Possibly the most
remarkable outcome following the introduction of PI and
combination therapy was the dramatic decrease in CNS
opportunistic diseases such as cryptococcal meningitis,
cerebral toxoplasmosis, primary CNS lymphoma, and
progressive multifocal leukoencephalopathy (d’Arminio
Monforte et al. 2004). In resource-limited settings these
CNS opportunistic diseases as well CNS infection by
Mycobacterium tuberculosis, Plasmodium species, and
other pathogens, remain common. Major deficiencies in
diagnostic technologies used to rule out these diseases
confound diagnosis and management of CNS disease in
these settings.
Reports of the prevalence and presentation of HIV-
associated neurocognitive disorders have demonstrated re-
markable variability across international studies and at present
a very limited amount of data is available on HAND in
resource-limited settings. For example, the prevalence of HIV-
Associated Dementia in sub-Saharan Africa has been reported
to be from as low as 3% (Belec et al. 1989) to as high as 54%
(Howlett et al. 1989), at least in part to due differences in
definition and ascertainment methods. In one of the earliest
international studies of HIV-associated cognitive impairment,
the World Health Organization found fairly consistent rates
of impairment on a relatively small test battery, of 19.1%
(Zaire), 15.3% (Kenya), 18.4% (Thailand), and 13.0%
(Brazil), and more substantial neurological impairment rates
of approximately 41% (Zaire), 40% (Kenya), 66% (Thailand),
and 54% (Brazil) in symptomatic individuals (Maj et al.
1994). Clifford et al. (2007) report that the International HIV
Dementia Scale, a brief screening tool, did not detect any
significant differences in cognitive status between HIV
positive and negative subjects in Ethiopia consistent with
clinical impression (Clifford et al. 2007). Contrastingly,
studies in India, China, and Uganda reported prevalence
rates of 56%, 34%, and 31% respectively (Heaton et al.
2008; Robertson et al. 2007a; Yepthomi et al. 2006). HIV-1
subtype C predominates in India, subtype B and CRF01_AE
in China, and subtypes A and D in Uganda. These
discrepancies could be the result of varying neurovirulence
of viral subtypes, different environmental factors, or a
consequence of underappreciated cultural nuances and
differences in the neuropsychological methods used in the
different studies.
In terms of the patterns of neuropsychological effects
observed across different countries, a pilot study investi-
gating the neurobehavioral effects of HIV-1 infection in
China reported a pattern of deficits in abstraction/executive
function, information processing speed, and learning
consistent with Western studies (Cysique et al. 2007b).
This study found no significant country effects on the
global neuropsychological score or measures of executive
function, attention, learning, memory, or motor functions,
although significant country effects on tasks of verbal
fluency and speed of processing were reported. In addition,
this study found that moderately high levels of depression
did not account for neuropsychological performance in
either the US or Chinese HIV positive groups, and that
neuropsychological performance did correlate with com-
plaints of cognitive difficulties in everyday life as well as
with unemployment status.
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In a larger study of former plasma donors in rural China,
Heaton et al. (2008) administered the same international
test battery to 203 HIV+ and 198 HIV− adults who were
mostly farmers (mean education = 5.6 years) (Heaton et al.
2008). Results of uninfected controls were used to create
demographically corrected neuropsychological norms,
which classified 37% of the HIV+ group as impaired. The
normed test results were sensitive to both HIV and Hepatitis
C virus (HCV) effects, as well as HIV disease severity
(AIDS status and history of severe immunosuppression).
Finally, participants classified as impaired reported more
cognitive difficulties in their everyday lives and decreased
independence in performing instrumental activities of daily
living (such as financial management, shopping, house-
keeping, and cooking).
Another study evaluating the pattern of neuropsychological
performance in a sample of HIV positive patients and
HIV negative control subjects in Uganda revealed signif-
icant group differences on measures of verbal learning and
memory, speed of processing, attention and executive
functioning (Robertson et al. 2007a). Gupta et al. (2007)
compared a sample of 119 adults in India infected with
HIV-1 subtype C who were not on antiretroviral therapy,
with normative data derived from an Indian sample of 540
healthy volunteers (with comparable gender distribution,
age, and education) and with a matched cohort of 126
healthy, HIV-1-seronegative individuals (Gupta et al. 2007).
They found a high rate (60.5%) of mild to moderate
cognitive deficits in the HIV patients but no evidence of
true dementia. The neuropsychological profile was charac-
terized by deficits in fluency, working memory, and
learning and memory, once again similar to patterns that
have been observed in the West.
A study reporting HIV-1 subtype-associated differences
in neurological disease was recently reported by Sacktor et
al. (2007), in a small Ugandan cohort. These investigators
found that subtype D was associated with higher dementia
prevalence than those with subtype A at similar disease
stage (Sacktor et al. 2007). Subtype D has also been
reported to be associated with faster progression of
systemic HIV disease (Kaleebu et al. 2002; Laeyendecker
et al. 2006). Robertson et al. (2008) reported substantial
differences in baseline neurocognitive test means across
seven resource limited countries (Malawi, South Africa,
Zimbabwe, Thailand, India, Peru and Brazil) between
unmatched groups of patients with low levels of co-
morbid conditions (Robertson et al. 2008). In the first
randomized clinical trial observing neurocognitive effects
of antiretroviral treatment in treatment naïve patients from
multiple resource limited settings, Robertson et al. (2009)
found substantial improvement across multiple time points
of follow up from week 24 out to week 96 across seven
RLS countries (Robertson et al. 2009). The analysis was
limited to 293 participants who were randomized to
treatment with didanosine enteric-coated (ddI) + emtricitabine
(FTC) + atazanavir (ATV) in the AIDS Clinical Trials Group
(ACTG) Study A5175 (PEARLS), and did not include groups
on alternate treatment regimens or untreated control groups
for comparison. Significant improvements in neuropsycho-
logical functioning after initiating antiretroviral therapy were
determined after controlling for baseline function, age, sex,
country, CD4, plasma HIV-1 RNA stratum, and years of
education. Notably, the magnitude of improvement in neuro-
cognitive functioning varied across the countries and could
not be explained by systemic disease factors. Improved
neurocognitive functioning may be due to control of HIV
viral load through antiretroviral effects, uncontrolled practice
effects on repeated test administrations, or both and demon-
strate the need for further normative comparison data
collection (including norms for change that consider practice
effects and normal test-retest variability) in resource limited
settings.
The studies above clearly demonstrate that HIV affects
the CNS and that existing neuropsychological instruments
can detect rather similar patterns regardless of country,
culture, or HIV-1 clade. Determining the relative impact of
these variables (country, culture, and clade) on severity of
neurological disease and neuropsychological impairment
however is not possible with available studies, due to
differences in inclusion/exclusion criteria, test instruments
and normative standards utilized, and systems used to
classify impairment as mild, moderate, or severe. Another
limitation of many previous studies of HAND in interna-
tional settings has been the lack of control or untreated
comparison groups. Investigators with limited time and
resources often have declined to enroll these groups for
comparison with infected and treated populations, but
including these groups in future longitudinal studies (as
well as cross-sectional) will add greatly to the interpret-
ability and scientific value of the results.
The Frascati guidelines (Antinori et al. 2007) described
above are a step in the right direction in terms of classifying
impairment with regard to neuropsychological perfor-
mance, everyday functioning, and presence of co-morbid
conditions that may cause or contribute to neurocognitive
impairment, but much work still needs to be done to
establish greater consistency in instruments and other
methods used across studies in order to approach accurate
cross population comparisons. Infrastructural deficiencies
and differences in assessment and diagnostic methods
across these studies obscure the interpretation of results
and impede international neuroAIDS research in general.
Determining which tests have the broadest international
applicability and what factors (cultural, educational, lin-
guistic, etc) affect the generalizability of norms will be
especially important to progress in this field.
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Challenges to Conducting Assessments
in Resource-Limited Settings
Some of the challenges to conducting assessments in
resource-limited settings include: the overwhelming disease
burden for clinicians in these settings, geographic factors
and infrastructural deficiencies, and a lack of neurological
and neuropsychological expertise. As an example of the
disease burden, an estimated 25 million people in sub-
Saharan Africa are infected with HIV and in areas of some
countries prevalence of HIV infection exceeds 30% (WHO/
UNAIDS 2008). The staggering levels of HIV disease
create an immense load on healthcare systems in these
regions that are also wrought with tuberculosis, malaria,
and other diseases. These and other commonly encountered
diseases which have their own CNS effects not only create
problems for studies trying to tease out the effects of HIV
on the nervous system, but can also overshadow the
importance of neuropsychological studies in general. When
so many people are in need of treatment for the direct
effects and symptoms of disease, justifying studies without
some direct benefit to patients can be difficult, especially
under conditions of extremely limited funding.
Hospitals and clinics in developing countries tend to be
available only in large cities and towns, forcing people to
travel long distances for medical care or participation in
studies. Deficiencies in paved roads and access to trans-
portation mean that people frequently travel on foot to
clinics in town. For longitudinal studies, this can have an
impact on both study drop-out and accrual. People in many
settings must weigh the potential benefits of temporary
access to free medication and treatment against the effort to
get to clinics and the expense of losing a valuable day of
work.
The lack of neurological and neuropsychological exper-
tise in many areas requires these specialists to either be
brought in from other countries to conduct studies
themselves, or to train local physicians and nurses to
perform the neurological examinations and neuropsycho-
logical assessments. In order for neurocognitive tests and
neurological evaluations to be effective research tools, and
to promote valid and reliable assessments, administration of
assessments must be standardized and remain consistent
across sites and examiners. To achieve this goal, formal
training of examiners and ongoing review of assessments
and training procedures is required. This could include
formal training of examiners at study sites, access to
training videos and slides for the neurological exam and
individual neuropsychological test instruments, and a set of
on-line quizzes to certify examiners. Planned conference
calls with investigators and team members from each site,
as well as periodic visits to the sites by the primary
investigators could be carried out for quality assurance.
Taking these measures helps to ensure the quality of
assessments and data and helps to ensure that examiner
drift does not occur over time. Building capacity and
infrastructure, and providing training to transfer neurolog-
ical and neuropsychological expertise to healthcare pro-
viders in underdeveloped areas undoubtedly will yeild
benefits well beyond HIV research, and will likely improve
healthcare as a whole in these areas.
Challenges to Interpreting Assessments in International
Settings
The challenges to interpreting neuropsychological assess-
ments in international settings arguably are more difficult
than those impeding the performance of assessments and
conducting studies in general. For example, although
psychometric properties of Western tests generally have
been well established in the US and other Western
countries, little is known about the reliability and validity
of such instruments in the rest of the world. The validity of
an assessment refers to whether or not the test, question, or
skill at hand has a common, shared meaning or existence in
the minds of both test-maker and test-taker. The reliability
of an assessment refers to whether or not the results on a
test or questionnaire (depression screen for example)
remain consistent for an individual (or group?), either
within an administration or over separate administrations.
Some of the challenges to the validity and reliability of
neuropsychological assessments in international settings
include determining which skills are not “pan-human”
(and therefore which tests of the skills may not be valid
in a new setting), translating and adapting tests to be
appropriate for a different language and culture, and
gathering adequate normative and control data for the
patient population in the new setting. In light of the variable
pattern of neurocognitive impairment across HIV-infected
individuals, group mean comparisons both across and
within populations may not be sufficient. For many
purposes (research as well as clinical) we need appropriate
norms to accurately classify individuals.
The majority of the cognitive and motor skills targeted
by neuropsychological assessments probably can be con-
sidered “pan-human,” but different cultural/educational
backgrounds likely emphasize or de-emphasize specific
abilities. Studies of normal populations from different
cultures have revealed differences in cognitive abilities
between ethnic groups on a number of standardized tests
(including IQ tests, tests of learning efficiency and problem
solving, etc.). The WHO-Neurobehavioral Core Test Battery
(WHO-NCTB) study, for example, showed significant
differences in performance on seven neurobehavioral tests
(Digit Symbol, Digit Span, Benton visual memory test/
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recognition form, Santa Ana dexterity test, Simple
Reaction Time, Pursuit Aiming II, and Profile of Mood
States) between Western (North American and European)
populations and people from cultures significantly differ-
ent from North America and Europe (Anger et al. 2000).
Other studies have observed performance differences across
cultures in measures of language (Llorente et al. 2004),
verbal memory and fluency (Razani et al. 2007a), simple
attention (Anger et al. 1993), simple visual attention (Paul
et al. 2007), information processing speed (Anger et al.
1993; Llorente et al. 2004), timed and sustained perfor-
mance tasks (Agranovich and Puente 2007; Anger et al.
1993; Byrd et al. 2004; Chung et al. 2003), spatial based
tests (Holding et al. 2004; Jahoda 1979; Mayes et al. 1988;
Rosselli and Ardila 2003), digit based tests (Hedden et al.
2002), and even perception (Nisbett and Miyamoto 2005).
On the other hand, similarities in performance on tests of
non-verbal skills (Hsieh and Tori 2007; Razani et al.
2007b), simple reaction time (Anger et al. 1993), simple
attention (Paul et al. 2007), visual retention (Anger et al.
1993), counting and summation (Hsieh and Tori 2007),
visuo-spatial measures of speed of processing (Hedden et
al. 2002), and motor based skills (Parsons et al. 2007) also
have been reported. At the present it is difficult to
determine whether group differences, if they exist, suggest
that the test may not be valid or only suggest that different
norms are needed. Groups of US patients in their 20 s and
80 s for example would perform differently on most tests,
but this does not mean the tests are invalid for either group.
The concept of “Test-wiseness” incorporates important
test taking skills acquired through incidental learning rather
than being taught directly in educational environments.
These skills are most powerfully acquired through experi-
ence in formal educational systems (Rosselli and Ardila
2003). Success on neuropsychological tests depends on
many behaviors valued in classroom settings (sit still and be
quiet, pay attention, use pen and pencil, take notes on
verbal instruction, copy designs, solve problems, and work
quickly to finish tests and keep up with class). In developed
countries, a high school education (10–12 years) usually
provides enough experience for well-practiced test-taking
skills, but the same may not be true for developing
countries. Schools in resource-limited settings are often
under funded and have high pupil-teacher ratios. In areas
where teachers are overburdened, school supplies are
scarce, and testing practices are less rigorous, the Western
phenomenon of “test-wiseness” may not be fully developed
in most people. For example, the Trail Making Test B is
easily performed by people from Western societies where
most have at least 10–13 years education, but it may be too
difficult for semi-literate populations or non-western soci-
eties with less experience working with numbers and letters
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measures task switching and executive functions by asking
the test-taker to connect randomly placed numbers and
letters in order while alternating back and forth between the
two sequences. Although semi-literate people may be able
to accurately recite numbers and the alphabet, they usually
retrieve the sequences much more slowly and this effect
may overshadow the so-called executive requirements that
the test was designed to emphasize. In addition to these
differences in educational environments, most students in
Western educational systems are encouraged to “work as
quickly and accurately as you can.” These seemingly
contradictory demands reflect the philosophy of Western
cultures, where assessment of cognition usually is associ-
ated with both speed and accuracy. In other cultures,
however, being smart means being cautious and thoughtful
which often results in slower, more deliberate test-taking.
Slower test taking could result in the false attribution of
cognitive symptoms if compared to Western normative
data. Several authors have confirmed this finding that
members of many cultures frequently perform slower in
timed tasks compared with US populations. Zairian
children performed more slowly on the Tactual Perfor-
mance Test than American and Canadian children in one
study (Boivin et al. 1995). Razani et al. (2007a) published
findings that a normal group of monolingual English-
speaking Anglo-Americans significantly outperformed an
ethnically diverse normal group on the Trail Making Test
part B as well as the Stroop Tests B and C (Razani et al.
2007a). In a comparison of US and Russian normal adults,
Agranovich and Puente (2007) reported a significant effect
of culture on the timed tests Color Trails Test and Ruff
Figural Fluency Test.
It is unclear whether such differences affect test validity
(sensitivity to disease or even relevance to everyday function-
ing) but these cultural differences definitely require different
normative standards to accurately interpret performance.
Again, due to differences in cultural values placed on concepts
of efficiency, timeliness, and deadlines, tests of “processing
speed” or timed tests in general tend to be performed very
poorly by people in many developing areas of the world
compared to Western standards (Agranovich and Puente
2007; Anger et al. 1993; Byrd et al. 2004; Cysique et al.
2007b). Nevertheless, in spite of the differences in perfor-
mance across international populations, tests of processing
speed clearly are quite sensitive to HIV disease in both types
of areas (Cysique et al. 2007b; Heaton et al. 2008; Robertson
et al. 2007a). Processing speed as well as other cognitive
traits may not be emphasized as much in non-Western
educational systems and in many non-Western jobs, but we
cannot assume it is an unimportant (or nonexistent) human
characteristic in non-Western populations.
Transferring existing neuropsychological instruments to
new settings, particularly resource-limited settings, is not a
simple task. In addition to cultural differences in skill sets,
differences in and even a total lack of formal education can be
factors especially in rural settings where lack of familiarity
with writing instruments, much less computers, place limi-
tations on assessments. Familiar stimuli in Western cultures
such as subways, escalators, and even certain foods and
animals, are unfamiliar and inappropriate for use in testing
people in other cultures. Visual, auditory, and other stimuli
therefore, may need to be redesigned for use in a particular
setting. In settings where other alphabets are standard for
example, the Trail Making Test has been replaced with the
Color Trails Test which removed the English alphabet from
the instrument. Investigators at the University of Miami
altered word lists and phrases in the instructions and certain
passages of six verbal learning, memory, and fluency instru-
ments in an attempt to make these instruments valid for use in
Hispanic populations (Wilkie et al. 2004).
Differences in language can be problematic in moving
tests between settings. In terms of translating and admin-
istering assessments, even professional and accurate trans-
lation does not remove all problems. Standard instructions
may not be easily translated verbatim and therefore should
be carefully tailored to the common language and idioms of
the target population so that accuracy of content and ease of
understanding are maintained. Some languages have no
words to describe a particular object and translation of
verbal stimuli, such as word lists, can lead to differences in
word length or difficulty which result in various items or
even an entire test being fundamentally different, either
more or less difficult. Differences in item difficulty may
become problematic on tests that have discontinuation rules
after a certain number of incorrect responses in a row,
especially if “early” items are less familiar in the new
culture. Nonetheless, since resources are usually strained
and many tests have demonstrated some validity, existing
tests will inevitably be translated and used in international
studies. When planning neuropsychological evaluations of
a group of people using tests developed in another culture
and language, at the very least, it is important that tests be
translated into the target language by a neuropsychologist
or professional fluent in the target language, and then back
translated by an independent professional translator with no
knowledge of the test instruments as an extra precaution
(Cysique et al. 2007b). The tests should then be adminis-
tered by a neuropsychologist or trained psychometrician
fluent in the target language and familiar with the culture of
the participants, since informal rapport often is needed to
maximize a patient’s motivation and cooperation. In any
event, it is also important to pilot the new translations with
the target population to ensure comprehension of the
instructions’ and the test content’s meanings.
In some regions of the world such as India, Indonesia, and
many African countries (Zambia and Nigeria for example)
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multiple languages and dialects are spoken by various
subgroups of people. The Eighth Schedule of the Constitution
of India recently increased the number of languages recog-
nized by “The Official Languages Act, 1963” from 14 to 22
official languages (“The constitution of india: The official
languages act 1963”). In fact, over 400 individual mother
tongues are spoken across India (Gordon 2005). The
existence of so many subgroups within some countries and
regions of the world creates considerable impediments to
translating tests and establishing normative data for those
regions. To gather normative data for the WHO/UCLA
Auditory Verbal Learning Test in India for example,
translating and administering the test and word lists in Hindi
dialects alone may be insufficient. When clinical study sites
are dispersed throughout the various regions of the country,
tests may need to be translated into any one of the other 21
official languages, depending on the dominant language of
the region. Translating and adapting tests, then gathering
normative data for each subgroup in a country based on
differences in language and culture, would be very costly
and time consuming, and therefore test publishers and other
private organizations that collect neuropsychological data
have been reluctant to undertake the task.
Collecting appropriate normative data for neuropsycho-
logical tests in new settings is often a daunting task,
requiring large sample sizes consisting of hundreds of
normal subjects to bring about the needed datasets. Factors
such as age in years, education, gender, and language are
essential for appropriate comparisons, but other differences
such as urban versus rural settings, ethnicity, and socioeco-
nomic factors often need to be addressed as well. Ideally, all
demographic characteristics that relate to test performance
in normal individuals will be considered (“corrected”) in
any norms that are developed (Heaton et al. 2008). In
addition to the cultural, linguistic, and financial obstacles to
gathering normative data described above, issues with
recruitment (clinics versus elsewhere), incomplete or
inaccurate medical histories, and management of confounds
(psychiatric, medical, and neurological) create added
difficulties. When many demographic variables must be
controlled, attaining adequate sample size with all levels of
all factors well represented can be a very expensive
undertaking. Funding agencies thus far have been unenthu-
siastic about supporting basic normative data collection,
and the private sector which stands to gain little financial
reward, has been even less enthusiastic. As a result, most
studies attempt to accrue local control groups for study-
specific comparisons; however, these may suffer from small
sample sizes with unique characteristics, and often will be
inadequate for developing standards for classifying impair-
ment of infected individuals.
In the future, it would be useful to explore the
generalizability of existing norms from other places
(Western and non-Western), especially those with similar
cultures and socioeconomic conditions, because available
resources will not permit development of separate norms
for every population on earth. In order to accomplish
this, first we need to know what factors (cultural,
educational, linguistic, economic, etc) affect generaliz-
ability, and then identify which populations share these
characteristics. For example, tests and norms developed
in the U.S. are commonly used throughout the Western
world (Europe and Australia) (Bornstein et al. 1993; Paul
et al. 2007; Portegies et al. 1993; Tozzi et al. 2005; Wright
et al. 2008) apparently with similar validity, so similar
generalizability across developing countries where people
share similar cultural and experiential backgrounds may
be possible.
Investigative Strategies
For maximum efficiency in identifying the presence or
absence of impairment (but not necessarily characterizing
its nature) tests included in international resource-limited
settings should be as brief as possible and easily
administered (such as by non-neurologist/psychologist),
and test batteries should sample a wide range of
cognitive abilities. Tests/test batteries must be chosen
with consideration for the background and current life
circumstances of the people with whom they will be
used. As previously mentioned, some tasks and test
stimuli may be unfamiliar, while others are not. People
may have different cognitive approaches to questions and
problems, which may change the inherent meanings of
results. Factor analyses may be helpful in identifying
constructs sampled by various tests in different places.
Determining the influence of culture on test performance
and validity of test instruments, however, is not a simple
“yes” or “no” question. The psychometric appropriate-
ness or adequacy of a test also incorporates test-retest
reliability, relation of performance to demographics,
relation to disease, and relation to everyday lives.
The NIMH Core Battery for Assessment of AIDS-
Related Changes (Butters et al. 1990), for example,
measures a wide range of abilities affected by HIV, but
many of the tests are not well validated in cross-cultural
settings and the length of the battery is a problem for many
settings (especially those that are resource-poor). The WHO
Neuropsychological Screening Battery is a bit shorter and
still measures a variety of abilities; however, the lack of
appropriate normative data tailored to different cultural
settings is an issue. Brief screening batteries such has the
International HIV Dementia Scale and the ACTG 5199
International Battery are very practical and measure mostly
motor-based skills which translate well across cultures, but
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they are not very sensitive or specific to HIV related effects.
Screening batteries may be highly efficient and cost
effective for identifying potential study participants when
a large pool of patients exists, but to identify milder
impairment and characterize the pattern of neurocognitive
disorder, longer batteries which tap multiple cognitive
domains are necessary. During the early stages of the HIV
epidemic White et al. (1995) compared 57 studies which
assessed the performances of HIV-1 seropositive asymp-
tomatic and HIV-1 seronegative individuals in order to
determine if it is possible to have cognitive deficits in
asymptomatic people (White et al. 1995). The authors
reported a median impairment rate of approximately 35% in
asymptomatic HIV-infected patients and also pointed out
that relatively comprehensive batteries (14 or more meas-
ures) were more likely to uncover the cognitive effects of
HIV. Two batteries developed for use in China (Cysique et
al. 2007b; Heaton et al. 2008) and Uganda (Robertson et al.
2007a) offer somewhat of a compromise between extensive
batteries and screening batteries. The batteries used in these
studies balanced the need to assess multiple domains with
the importance of culturally valid test instruments and
relatively short administration time. For a comparison of
neuropsychological test batteries used in both the US and
internationally see Tables 1 and 2.
Conclusions
In summary, there are many challenges to the assessment of
neurocognitive effects of HIV in resource-limited settings,
including an overwhelming disease burden (HIV as well TB,
malaria, and other infections), lack of infrastructure (including
paved roads, access to clinics, and modern medical technol-
ogy), lack of neuropsychological and neurological expertise,
differences in education, culture, and language across borders,
and a lack of appropriate normative data for many patient
populations. Regardless of the challenges to international HIV
neuropsychological studies, when studies are conducted with
a standardized approach to assess cognition and rate levels of
impairment, and when appropriate normative or control data
are available, meaningful results can be obtained. While it is
certainly not fair to directly compare (without re-norming)
neuropsychological test performance in resource-limited
settings with data from populations in Western cultures,
existing neuropsychological test instruments have demon-
strated sensitivity to HIV-associated neurocognitive effects in
international studies and therefore can still be useful. Since
tests and normative data developed in the US have demon-
strated validity in Europe and Australia, identifying which
factors (cultural, educational, linguistic, economic, etc) affect
the generalizability of test results and which populations in
various resource-limited settings share these characteristics
will be important for future studies attempting to compare
performance across international populations.
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